Henry Rath
Plus aucun poste en cours
Profil
Henry Rath worked as an Executive Director of Corporate Development at Amgen, Inc. from 2003 to 2012.
He also worked as a Senior Vice President of Business Development at Seres Therapeutics, Inc. and as a Senior Manager of Strategy and Business Development at Baxter BioScience Corp.
In addition, he was a Vice President of Business Development at Astria Therapeutics, Inc. and a Member of the Biotechnology Group at The Lek.
He was also a Member at Oppenheimer & Co., Inc. Mr. Rath holds an MBA from The Wharton School of the University of Pennsylvania and an undergraduate degree from Harvard College.
He is currently working as the Chief Business Officer at Surface Oncology, Inc.
Anciens postes connus de Henry Rath
| Sociétés | Poste | Fin |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 08/09/2023 |
| AMGEN INC. | Corporate Officer/Principal | 01/05/2012 |
| SERES THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Oppenheimer & Co., Inc.
 Oppenheimer & Co., Inc. Investment ManagersFinance Oppenheimer & Co., Inc. provides security brokerage services. It also offers investment banking and advice to high net worth investors, individuals, businesses and institutions. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
The Lek/Alcar Consulting Group, Inc.
 The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
Formation de Henry Rath
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Harvard College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ASTRIA THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Baxter BioScience Corp.
 Baxter BioScience Corp. BiotechnologyHealth Technology Baxter BioScience Corp. provides biopharmaceutical and vaccines services. It offers a portfolio of therapeutic proteins derived from either human plasma or recombinant technology. The company is headquartered in Beltsville, MD. | Health Technology |
The Lek/Alcar Consulting Group, Inc.
The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
Oppenheimer & Co., Inc.
Oppenheimer & Co., Inc. Investment ManagersFinance Oppenheimer & Co., Inc. provides security brokerage services. It also offers investment banking and advice to high net worth investors, individuals, businesses and institutions. The company is headquartered in New York, NY. | Finance |
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |